Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
[HTML][HTML] BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
IS Pagani, P Dang, IO Kommers, JM Goyne… - …, 2018 - ncbi.nlm.nih.gov
Accurate quantification of minimal residual disease (MRD) during treatment of chronic
myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR …
myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Different kinetic patterns of BCR‐ABL transcript levels in imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response
YZ Qin, YR Liu, HH Zhu, JL Li, GR Ruan… - International Journal …, 2008 - Wiley Online Library
Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and …
S Branford, JF Seymour, A Grigg, C Arthur… - Clinical Cancer …, 2007 - AACR
Purpose: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
[HTML][HTML] Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
G Martinelli, I Iacobucci, G Rosti, F Pane, M Amabile… - Annals of oncology, 2006 - Elsevier
Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
[HTML][HTML] Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with …
Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …